Immuron Limited provided shareholders and the market with an update on the company s clinical development portfolio. The NMRC has recently completed the in-patient stage of the campylobacter challenge.
Clostridioides difficile risk is significantly higher in Korean patients with inflammatory bowel disease (IBD), which is comparable to the trend observed in Western patients with IBD.
New research published in Infection Control & Hospital Epidemiology reveals that patients staying in a hospital bed previously occupied by someone with a Clostr
Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.
November’s Gastroenterology Month in Review features an FDA approval, the discontinuation of a phase 3 clinical program, and news about Clostridioides difficile testing and risk factors.